An update from Atara Biotherapeutics ( ($ATRA) ) is now available. On December 30, 2025, Atara Biotherapeutics amended its commercialization ...

The average one-year price target for Atara Biotherapeutics (NasdaqGS:ATRA) has been revised to $20.06 / share. This is an increase of 15.69% from the prior estimate of $17.34 dated December 3, 2025.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, ...

Iovance Biotherapeutics (IOVA) has been grinding through a tough stretch in the market, and that slump is exactly why the stock is starting to catch more value-focused attention. See our latest ...

If you are wondering whether Iovance Biotherapeutics is a beaten down bargain or a value trap, you are not alone. This stock sits at the crossroads of high risk and potentially high reward. Despite ...

The ongoing phase I/II clinical trial is evaluating the safety, tolerability and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001 Preliminary findings include a ...

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets The agreement - OBT's second high-profile ...

GSK (GSK.L) continues to strengthen its oncology portfolio, this time with a new regulatory designation for risvutatug rezetecan in the US and a cancer drug discovery collaboration with UK-based ...

Several medical treatments, particularly for genetic ailments, rely on symptomatic management instead of correcting the causative issue. Precision biotherapeutics bring together genetic science, ...

JCR Pharmaceuticals’ unique brain-shuttling technology opens new treatment opportunities for meeting the needs of patients grappling with CNS diseases. Getting drugs from the bloodstream into the ...

Gene silencing has become a powerful therapeutic approach that has transformed the treatment paradigm for certain conditions, especially a handful of poorly treated rare diseases. Rather than directly ...